UNSPSC 51282326: Erythromycin salnacedin

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C12H13NO5S.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VMA8F29A76, chemically known as erythromycin, compound with n-acetyl-l-cysteine 2-hydroxybenzoate (ester) (1:1), dihydrate, but more generally known as erythromycin salnacedin, which bears US NIH Compound Identifier 60940. European Medicines Agency schedules erythromycin salnacedin or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG.

UNSPSC 51282326 Erythromycin salnacedin is a Commodity code nominally identifying a specific pharmaceutical product, but recent state and local activity shows little direct procurement of this agent itself. Instead, the opportunities tagged under this code involve broader pharmaceutical and medical supply acquisition — naloxone procurement for community health programs, generic multi-source pharmaceutical contracting through cooperative purchasing vehicles, direct-to-manufacturer prescription programs, and medical and first aid supplies for emergency response. The issuing bodies are diverse: county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal purchasing departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across participating jurisdictions including Oregon). The work spans acquisition of finished pharmaceutical products, emergency medical consumables, and pharmacy benefit management arrangements rather than manufacturing or active pharmaceutical ingredients.

Recent procurement activity is concentrated in Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple states. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the City of Tampa's Bid 26-P-00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00 and sheltered for certified Small Local Business Enterprises with a 5 percent bid discount; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers with awards effective July 1, 2026; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) regarding direct-to-manufacturer prescription programs for therapeutic pharmacy initiatives. The code shows substantial recent activity but mismatches the nominal product scope — vendors pursuing this code should position around pharmaceutical supply chain, emergency medical consumables, and pharmacy benefit program support rather than erythromycin salnacedin specifically.